rosiglitazone has been researched along with Lymph Node Metastasis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, FZ; Li, J; Mo, XM; Wang, QP; Zhang, L | 1 |
| Bae, YK; Cho, SJ; Choi, IJ; Kim, YW; Kook, MC; Lee, JH; Park, J; Ryu, KW; Shin, JY | 1 |
2 other study(ies) available for rosiglitazone and Lymph Node Metastasis
| Article | Year |
|---|---|
Effects of rosiglitazone on the growth and lymphangiogenesis of human gastric cancer transplanted in nude mice.
Topics: Animals; Cell Proliferation; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Humans; Lymphangiogenesis; Lymphatic Metastasis; Mice; Mice, Nude; RNA, Messenger; Rosiglitazone; Stomach Neoplasms; Thiazolidinediones; Vascular Endothelial Growth Factor C; Vascular Endothelial Growth Factor Receptor-3 | 2013 |
Peroxisome proliferator-activated receptor γ upregulates galectin-9 and predicts prognosis in intestinal-type gastric cancer.
Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Survival; Epithelial-Mesenchymal Transition; Galectins; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Neoplasm Invasiveness; Neoplasm Transplantation; PPAR gamma; Prognosis; Promoter Regions, Genetic; Proportional Hazards Models; Protein Binding; Rosiglitazone; Stomach Neoplasms; Thiazolidinediones; Up-Regulation; Zebrafish | 2015 |